CagriSema vs Retatrutide: What Differs

CagriSema and retatrutide are two different molecules built on two different mechanisms, tested in separate Phase 3 trial programs, and neither one is approved by the FDA as of this writing. CagriSema pairs cagrilintide, an amylin analog, with semaglutide, a GLP-1 receptor agonist. Retatrutide is a single molecule that activates three receptors at once — GLP-1, GIP, and glucagon. The question people ask next is which one produced bigger numbers in its trials, and the answer depends on which trial and which endpoint.

How the two compounds differ

What is CagriSema, mechanistically

CagriSema is not a new molecule in the way retatrutide is — it is a fixed-ratio combination of two existing mechanisms delivered in one injection. Cagrilintide mimics amylin, a hormone the pancreas releases alongside insulin that slows gastric emptying and contributes to satiety signaling. Semaglutide is the same GLP-1 receptor agonist marketed as Ozempic and Wegovy. The idea behind pairing them is that amylin and GLP-1 act on different, complementary pathways in the brain's appetite-regulation centers, so combining the two produces an effect larger than either alone.

That combination was tested in REDEFINE 1, a trial in adults with overweight or obesity without diabetes, and REDEFINE 2, a trial in adults with overweight or obesity and type 2 diabetes. Garvey et al., NEJM 2025 reported the REDEFINE 1 results, and Davies et al., NEJM 2025 reported REDEFINE 2. Both trials measured body weight change over roughly a year of treatment against placebo, in randomized, controlled designs.

What is retatrutide, mechanistically

Retatrutide takes a different approach: instead of combining two separate molecules, it is one peptide engineered to bind three receptors — GLP-1, GIP, and the glucagon receptor — on the theory that glucagon receptor activation adds an energy-expenditure component that GLP-1 and GIP alone don't provide. Jastreboff et al., NEJM 2023 reported the Phase 2 obesity trial results, and the compound moved into Phase 3, reported by Jastreboff et al., NEJM 2026. Retatrutide has also been studied in type 2 diabetes: Rosenstock et al., Lancet 2023 reported a Phase 2 trial in that population.

For comparison, Jastreboff et al., NEJM 2022 reported the SURMOUNT-1 trial of tirzepatide, the dual GLP-1/GIP agonist marketed as Mounjaro and Zepbound — a useful middle point between a dual agonist and retatrutide's triple-receptor design, and between tirzepatide and CagriSema's amylin/GLP-1 pairing.

Which trial measured what

It matters to be precise here, because these are not head-to-head trials against each other — CagriSema and retatrutide have never been tested in the same study, against the same placebo group, at the same time. REDEFINE 1 and REDEFINE 2 measured CagriSema against placebo in two distinct populations. The Phase 2 and Phase 3 retatrutide trials measured retatrutide against placebo, in trials run by a different sponsor on a different timeline. Any claim that one produced "more weight loss" than the other is a cross-trial comparison, not a controlled one, and the populations, durations, and background care in each trial differ enough that a direct ranking isn't something the literature supports.

Development status and the FDA

Neither molecule is approved by the FDA. CagriSema and retatrutide are both in Phase 3 development as of this writing, with trial results published but no regulatory approval granted to either. This differs from the related, already-approved drugs in the same drug class: semaglutide is approved by the FDA as Ozempic and Wegovy, and tirzepatide is approved by the FDA as Mounjaro and Zepbound, per Wilding et al., NEJM 2021 and the SURMOUNT-1 trial cited above. PeptoClinic's retatrutide is not Mounjaro, Zepbound, Ozempic, or Wegovy, and it is not approved by the FDA — it is the same molecule studied in the trials cited here, supplied as a vial. CagriSema is not currently part of PeptoClinic's catalog.

Where the two fit in the broader picture

Both molecules sit in the incretin-and-beyond category that started with GLP-1-only drugs and has expanded toward multi-receptor designs. PeptoClinic's catalog carries retatrutide, tirzepatide, and semaglutide, each reflecting a different receptor strategy within that same research area — a useful reference point for anyone trying to map how cagrilintide-based and triple-agonist approaches relate to the drugs already in pharmacies. Every vial PeptoClinic ships is analyzed by Janoshik Analytical, the same laboratory that produced the certificates covering the compounds in the catalog; current pricing lists what is in stock.